The combined TGII from a panel of CRC PDXs revealed that GC1118 treatment inhibited tumor growth significantly better than cetuximab in KRAS-mutants (Figure 3 and Table S2); however, complete tumor regression was not observed. The gene discussed is KRAS; the disease is colorectal carcinoma.